

Philips showcases commitment towards Nuclear Medicine

27 June 2018 | News

Portfolio includes unique solutions that enhance the patient experience and support diagnostic confidence

PHILIPS Healthcare

Royal Philips, a global leader in health technology, has announced that it is highlighting its portfolio of molecular imaging solutions at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2018 Annual Meeting in Philadelphia, PA. With innovations such as time-of-flight PET and digital PET/CT, Philips is continuing to advance molecular imaging solutions to help seamlessly connect data and technology to enable a better patient experience, confident diagnosis and improved clinical outcomes. "With an increasing number of radiopharmaceuticals entering the market, along with new developments impacting oncology and cardiology, molecular imaging innovation is advancing at an unprecedented rate.

As the industry shifts from volume- to value-based care, the need for an accurate treatment pathway is more important than ever," said Piotr Maniawski, Director of Clinical Science, Nuclear Medicine, Philips. "Philips is making significant strides in nuclear medicine with innovations such as the Vereos Digital PET/CT, which is gaining momentum globally and enabling hospitals to make an immediate impact on outcomes, increasing diagnostic confidence." During the meeting, Philips was recognized with the "Best of Service" award for PET imaging by IMV ServiceTrak.

Philips is committed to providing its customers with service that goes beyond reacting to problems, taking a proactive and preventative approach to drive performance. By combining systems, software and services to deliver integrated, tailored solutions, Philips is helping providers deliver better healthcare through increased staff efficiency and improved patient satisfaction.